Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

NCT06358638 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Daratumumab
DRUG: Alemtuzumab
DRUG: Sirolimus
RADIATION: Total Body Irradiation

Sponsor

Children's National Research Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]